Monitoring rules for toxicity in Phase II oncology trials
نویسندگان
چکیده
Anastasia Ivanova*,1, Guochen Song2, Olga Marchenko2 & Stergios Moschos3 Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA Quintiles, 5927 South Miami Boulevard, Morrisville, NC 27560, USA Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA *Author for correspondence: Tel.: +1 919 843 8086 Fax: +1 919 966 3804 [email protected]
منابع مشابه
Continuous toxicity monitoring in phase II trials in oncology.
The goal of a phase II trial in oncology is to evaluate the efficacy of a new therapy. The dose investigated in a phase II trial is usually an estimate of a maximum-tolerated dose obtained in a preceding phase I trial. Because this estimate is imprecise, stopping rules for toxicity are used in many phase II trials. We give recommendations on how to construct stopping rules to monitor toxicity c...
متن کاملResponse to neoadjuvant chemotherapy in locally advanced gastric and gastroesophageal cancer: Phase II clinical trial
Background: Gastric cancer is an important health problem across the world. Chemotherapy in combination with local treatment is standard treatment for locally advanced gastroesophageal cancers. The purpose of this investigation was evaluation of response and tolerability to neoadjuvant EOX regimen in locoregionally advanced gastric cancer. Materials and Methods: patients with locoregionally adv...
متن کاملDesign considerations for dose-expansion cohorts in phase I trials.
Phase I trials are increasingly including dose-expansion cohorts after the maximum-tolerated dose (MTD) has been reached to better characterize the toxicity profile or identify early signs of efficacy within a specific disease population. This article provides guidelines on how to monitor safety and re-evaluate the MTD using data obtained from expansion cohorts of phase I protocols. We illustra...
متن کاملPharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?
Many clinical trials of oncology drugs now include at least a consideration of pharmacogenomics, the study of germline or acquired genetic factors governing a drug's response and toxicity. Besides the potential benefit to patients from the consideration of personalized pharmacogenomic information when making treatment decisions, the incentive is clear for oncology drug developers to incorporate...
متن کاملPhase II logistic profile monitoring
In many industrial and non-industrial applications the quality of a process or product is characterized by a relationship between a response variable and one or more explanatory variables. This relationship is referred to as profile. In the past decade, profile monitoring has been extensively studied under the normal response variable, but it has paid a little attention to the profile with the ...
متن کامل